Nov 27, 2019 — 5 min read
Lunit, a leading medical AI software company, will present its latest and most up-to-date AI software for radiology—Lunit INSIGHT CXR and Lunit INSIGHT MMG—at the upcoming RSNA 2019. The products are installed globally for clinical use in Mexico, UAE, China, Thailand, Taiwan, and South Korea. Lunit is one of the leaders and pioneers in digital healthcare, selected by CB Insights as one of the “Digital Health 150” companies this year.
During RSNA 2019, Lunit will be presenting the latest version of its AI solution for chest x-ray, Lunit INSIGHT CXR—which had gained CE mark recently—and for mammography, Lunit INSIGHT MMG. The software has been first introduced in RSNA 2017 and 2018 respectively.
According to Lunit, the chest x-ray software product has been highlighted recently in major publications such as Radiology, Scientific Reports, and JAMA Open Network. The publications validate the performance of the chest radiography algorithm (Lunit INSIGHT CXR) as well as its clinical value in an emergency department and TB screening setting.
The algorithm for breast cancer detection, Lunit INSIGHT MMG, has also displayed top-level performance in the detection of breast cancer, upon multiple reader studies. “The studies show that when the readers use our software, it lead to an increase in breast cancer detection by 24%,” said Hyo-Eun Kim, PhD, Head of Breast Radiology at Lunit. “This shows that our product can provide tangible benefits to both physicians and patients, detecting more breast cancer and reducing invasive, unnecessary biopsies.”
Merely 1-2 years since its launching, Lunit AI software system has gone through major improvements—not only in its algorithmic performance but also in user compatibilities such as user interface and report generation, to facilitate better workflow.
“We have conducted on-site interviews with our customers all throughout the year,” said Minhong Jang, Chief Business Officer of Lunit. “We listen to what they have to say, both the positive and the negative comments, and align with their needs to make the product useful and helpful for the radiologists in the field.”
Since the beginning of the year until recently, the company saw an increase in the number of images analyzed with commercially installed Lunit INSIGHT in a clinical setting. With installations in multiple global sites, Lunit INSIGHT products are quickly expanding its presence in the international market.
“It is true that the software showed some false positives upon its initial installation earlier this year,” said a radiologist who uses Lunit INSIGHT CXR for daily clinical interpretations. “However, with subsequent update in the software, I noticed a significant decrease in the appearance of false positives. It has been a much satisfying improvement. Now, with AI, I feel like I have a double-checking, safety net system.”
“We’ve been through extensive developments in the past year, which includes partnerships with major players in the industry,” said Brandon Suh, MD, CEO of Lunit. “We have a strong ongoing partnership with FUJIFILM and others like NVIDIA, EnvoyAI, and INFINITT, and also added new partnerships with Microsoft and more. We look forward to reaching further milestones with these partners and together create meaningful and impactful changes in digital health.”
One of the most mature products—Lunit INSIGHT CXR—has recently received a CE mark, now ready for sales in the European market. The mammography solution, Lunit INSIGHT MMG is expected to get CE certification by the end of this year. FDA clearance is expected by 2020. These products will be available for demonstration during RSNA, not only at Lunit booth, but also displayed at following booths: FUJIFILM REiLi station, GE Healthcare, EnvoyAI, and INFINITT.
At RSNA this year, Lunit's researchers will be presenting seven abstracts, and Suh will be on stage at the AI Theater to present Lunit's recent achievements and future developments.
Since its first attendance at RSNA back in 2016, this is Lunit’s fourth year as an exhibitor. In 2016, the objective was to let the attendees know of its groundbreaking AI technology and research. In 2017, the company showcased its first software product, Lunit INSIGHT CXR, and Lunit INSIGHT MMG the following year.
“We’re growing with years of attendance in RSNA,” said Suh. “Every year, we see the AI pavilion enlarged in scale and importance. We are happy to see that the acceptance of advanced technology within the medical society is being amplified. We look forward to meeting more people at RSNA this year.”
Click here to visit Lunit Virtual Press Office at RSNA
Lunit is a medical AI software company devoted to developing advanced medical image analytics and novel imaging biomarkers via cutting-edge deep learning technology. Founded in 2013, Lunit has been internationally acknowledged for its advanced, state-of-the-art technology and its application in medical images with high accuracy and efficiency. Lunit’s AI solution for chest x-ray and mammography, Lunit INSIGHT, is currently in use at different locations around the world—Mexico, UAE, China, Thailand, Taiwan, and Korea. Lunit is based in Seoul, South Korea.
Lunit wins Tumor Proliferation Assessment Challenge (TUPAC) 2016
Lunit to unveil data-driven imaging biomarker at RSNA 2016
Lunit to showcase AI-powered products at USCAP 2017
Lunit INSIGHT: The First-ever, Real-time Imaging AI Analytics on the Web
Cognitive biases and augmented intelligence in radiology
Lunit Returns to RSNA with Real-time Imaging Platform, Featuring Cloud-based A
Lunit Unveils “Lunit INSIGHT,” A New Real-time Imaging AI Platform on the Web at RSNA 2017
Lunit INSIGHT: Q&A with Brandon B. Suh, Chief Medical Officer at Lunit
Media Advisory: Lunit at RSNA 2018
Lunit Opens “Lunit INSIGHT for Mammography” for Public Access
Lunit Brings its Newest AI Solution for Mammography to RSNA 2018
Lunit Partners with Fujifilm and Salud Digna to Provide Medical AI Solution in Mexico
Lunit announces new members in its advisory board: Dr. Eliot Siegel, Dr. Linda Moy, and Dr. Khan Siddiqui
Lunit to Introduce Medical AI Solutions at GTC 2019
Lunit to Present Abstracts on AI-powered Precision Pathology at 2019 AACR Annual Meeting
Lunit to Showcase AI Solution for Breast Cancer at SBI 2019
Lunit to Present Findings on the Predictive Power of AI Biomarker for Lung Cancer Immunotherapy at ASCO 2019
Lunit Receives Korea MFDS Approval for its AI Solution for Breast Cancer, Lunit INSIGHT MMG
Lunit Gets Korea MFDS Approval for its AI Solution for Chest X-ray, Lunit INSIGHT CXR 2
Lunit at RSNA 2019
Lunit Announces its First CE Mark for AI-Powered Chest X-ray Analysis Software, Lunit INSIGHT CXR
AI-assisted Radiologists Can Detect More Breast Cancer with Reduced False-positive Recall
Lunit Releases Its AI Online to Support Healthcare Professionals Manage COVID-19
Lunit to Present Findings on the Predictive Power of AI-based Analysis of Immune Phenotype at ASCO 2020
Lunit INSIGHT MMG, an AI Solution for Breast Cancer Detection, Now CE Certified
AI Solution for COVID-19, Developed by Medical AI Firm Lunit, Now Has Users in More Than 10 Countries
Lunit at ECR 2020: Providing Virtual Exhibition and Online Presentations
Emergent Connect Partners with Lunit to Provide Cloud Based AI Solutions
AI Analysis Can Improve Lung Cancer Detection on Chest Radiographs
AI has Added Value in Insurance Underwriting Process, Recent Pilot Project Between Lunit and Cathay Financial Innovation Lab Reveals
RSNA 2020--Lunit Collaborates with Global Giants in Presenting its AI Solution at Virtual Booths of GE Healthcare, FujiFilm, and Sectra
AI Proves Its Value in Assistance for Emergency Cases-- With Higher Accuracy and Timely Reporting Time of Chest Radiographs
Lunit Expands Collaboration with GE Healthcare to Advance AI Adoption across Healthcare Industry
AI Can Offer Fast and Reliable Examination to Triage COVID-19 Patients-- A Multicenter Retrospective Study Reveals
Recent Studies Reveal High Performance of Lunit AI in Breast Cancer Detection
South Korean Medical AI Provider and PACS Leader Enters Indonesian Market, to Help COVID-19 Screening and Diagnosis
What do the medical journals say about AI-powered mammography?
Research Using Lunit Demo Website
Lunit Presents AI-powered Pathologic Classification of Immune Phenotype that Predicts Response to Immunotherapy at USCAP 2021
What do the medical journals say about AI-powered chest x-ray interpretation?
Join our webinar with Dr. Fredrik Strand
From retrospective to prospective trials of AI in breast cancer screening
AACR 2021 - Lunit Presents Abstracts Demonstrating the Potential of its AI Biomarker in Cancer Treatment
Will AI Identify Breast Cancer Better Than Radiologists in Actual Clinical Screening?
Case of the Month | Where Is Breast Cancer?
AI-based Analysis of Cancer Tissue Predicts Response to Immunotherapy--Findings to Be Presented at ASCO 2021